Smartlens: Funding, Investors & Team (Sep 2026)
Smartlens is an innovative medical technology company specializing in the treatment and diagnosis of Glaucoma, a chronic eye disease that leads to irreversible blindness. Through their clinical trials, they are testing a groundbreaking contact lens called miLens, which monitors eye pressure (IOP). This technology aims to improve the outcomes of Glaucoma treatment as the disease currently affects millions of people worldwide, with a significant number of cases going undiagnosed or leading to blindness despite ongoing treatment. The monitoring of eye pressure outside of clinical settings has been recognized as an urgent priority by leaders in ophthalmology. Smartlens' flagship product, miLens, offers a non-invasive and convenient way to monitor eye pressure anytime and anywhere, enabling early diagnosis, personalized treatments, and ongoing disease monitoring. This will ultimately reduce the prevalence of blindness, treatment costs, and the overall burden on individuals and economies. The unique sensor technology used in miLens is owned and protected by Smartlens, Inc., with patents covering over 40 countries. Additionally, Smartlens' technology is being studied at Stanford University Labs for monitoring intracranial pressure (ICP) associated with certain neurological disorders and cancers. The company also possesses a non-invasive drug delivery technology that monitors IOP and administers medication at appropriate times to enhance effectiveness, patient compliance, and minimize side effects. Smartlens has received recognition for its innovation, including winning the 2021 "Outstanding Innovation in Medical Technology and Life Sciences" award by Octane. They have been invited to numerous national and international conferences, published their research, and gained media coverage from reputable sources such as ABC7, Fortune, BBC, and Nature Medicine.
Smartlens has raised $11.3M across 2 funding rounds on record, the most recent an undisclosed round of $5.2M announced in Oct 2025.
That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Smartlens Company Profile and Key Stats
Latest funding round on record: Oct 2025.
Smartlens Funding Rounds
Smartlens raised $6.1M in a Series A announced in Jul 2023.
2.3 years later, an undisclosed round of $5.2M was announced in Oct 2025.
Smartlens Founders and Leadership Team
Contact details for the Smartlens team: 2 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Smartlens Funding Compared to Other Health Care Startups
Smartlens' latest round of $5.2M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Smartlens in Health Care and Mountain View
Companies Similar to Smartlens
https://metriport.com
There are too many reasons why Healthcare is unaffordable in the U.S, but one of the largest is waste. Up to…
Serif Health provides healthcare price intelligence and contract management solution.
Switchboard Health provides virtual care solutions to payers, health systems, employers, and at-risk…
Astek Diagnostics has designed a system that helps doctors choose the right antibiotics for patients…
TECLens is developing a crosslinking technology that can effectively address vision problems in both healthy…
Healthcare Shares operates as a crowdfunding portal for the transformative medical innovations of the future.
Gradient Health collaborates with medical data providers worldwide to assemble diseases and conditions for AI…
Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s…
Happy Health is a mission-driven technology company committed to transforming mental health awareness through…
Leal Therapeutics creates new treatments for patients.
Teal Health is on a mission to empower women when it comes to their health – starting with at-home cervical…
Smartlens Funding FAQs
What does Smartlens do?
Smartlens is an innovative medical technology company specializing in the treatment and diagnosis of Glaucoma, a chronic eye disease that leads to irreversible blindness. Through their clinical trials, they are testing a groundbreaking contact lens called miLens, which monitors eye pressure (IOP). This technology aims to improve the outcomes of Glaucoma treatment as the disease currently affects millions of people worldwide, with a significant number of cases going undiagnosed or leading to blindness despite ongoing treatment. The monitoring of eye pressure outside of clinical settings has been recognized as an urgent priority by leaders in ophthalmology. Smartlens' flagship product, miLens, offers a non-invasive and convenient way to monitor eye pressure anytime and anywhere, enabling early diagnosis, personalized treatments, and ongoing disease monitoring. This will ultimately reduce the prevalence of blindness, treatment costs, and the overall burden on individuals and economies. The unique sensor technology used in miLens is owned and protected by Smartlens, Inc., with patents covering over 40 countries. Additionally, Smartlens' technology is being studied at Stanford University Labs for monitoring intracranial pressure (ICP) associated with certain neurological disorders and cancers. The company also possesses a non-invasive drug delivery technology that monitors IOP and administers medication at appropriate times to enhance effectiveness, patient compliance, and minimize side effects. Smartlens has received recognition for its innovation, including winning the 2021 "Outstanding Innovation in Medical Technology and Life Sciences" award by Octane. They have been invited to numerous national and international conferences, published their research, and gained media coverage from reputable sources such as ABC7, Fortune, BBC, and Nature Medicine.
How much funding has Smartlens raised?
Smartlens has raised $11.3M across 2 rounds on record. The most recent is an undisclosed round of $5.2M announced in Oct 2025.
When did Smartlens last raise funding?
Smartlens' most recent funding round on record is an undisclosed round of $5.2M, announced in Oct 2025.
Who founded Smartlens?
FundedIQ lists Sevda Agaoglu (Founder) at Smartlens.
Who is the CEO of Smartlens?
Savas Komban is listed as CEO at Smartlens.
Where is Smartlens headquartered?
Smartlens is based in Mountain View, California, United States.
How many employees does Smartlens have?
Smartlens is in the 1-10 employee band.
How does Smartlens' funding compare to other Health Care startups?
Smartlens' latest round of $5.2M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Smartlens Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Smartlens is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.